文献速递炎症性肠病

戈利木单抗治疗溃疡性结肠炎患者2a期开放标签试验中预测应答的基因表达特征

Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis.
PubMed 文献 · Gastroenterology · 2018-07-04

本研究为2a期开放标签试验,纳入103例接受戈利木单抗治疗的中重度溃疡性结肠炎患者,检验基线基因表达特征能否预测第6周和第30周的黏膜愈合、临床应答和临床缓解。该特征预测第6周黏膜愈合的AUCROC为0.688(P=.002),第30周为0.671(P=.006),敏感度87%但特异度仅34%,未能以统计学显著性预测临床缓解或临床应答。

要点

  • 基线基因表达特征可预测戈利木单抗治疗第6周黏膜愈合,AUCROC为0.688(P=.002)。
  • 该特征预测第30周黏膜愈合的AUCROC为0.671(P=.006),敏感度87%、特异度34%。
  • 该特征未能以统计学显著性预测临床缓解或临床应答。

核心结论

  • 基线基因表达特征可预测戈利木单抗治疗中重度溃疡性结肠炎患者的黏膜愈合,但特异度低限制其临床效用,且不能以统计学显著性预测临床缓解或临床应答。
  • 需要进一步研究识别能预测溃疡性结肠炎患者对抗肿瘤坏死因子药物应答的生物标志物。

研究设计与样本

  • 2a期开放标签研究,纳入103例接受戈利木单抗治疗的中重度溃疡性结肠炎患者,检验治疗前结肠活检基线基因表达特征对第6周和第30周黏膜愈合、临床应答和临床缓解的预测价值。
  • 临床试验注册号:ClinicalTrials.gov NCT01988961。

主要发现

  • 基线基因表达特征预测第6周黏膜愈合的AUCROC为0.688(P=.002),预测第30周黏膜愈合的AUCROC为0.671(P=.006)。
  • 该特征识别黏膜愈合的敏感度为87%,特异度仅34%。
  • 基线基因表达特征未能以统计学显著性识别后续达到临床缓解或临床应答的患者。

局限性

  • 该特征识别黏膜愈合的敏感度为87%,但特异度仅34%,限制其临床效用。
  • 需要进一步研究识别能预测溃疡性结肠炎患者对抗肿瘤坏死因子药物应答的生物标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Golimumab, a tumor necrosis factor antagonist, is an effective treatment for patients with moderate-to-severe ulcerative colitis (UC); however, more than 50% of initial responders lose their response to the drug within the first year of therapy. A gene expression signature identified in colon biopsies collected before treatment was associated with response to infliximab, and was subsequently refined to associate with mucosal healing in response to golimumab. We performed a phase 2a open-label study of 103 golimumab-treated patients with moderate-to-severe UC to test whether the baseline gene expression signature could be used to predict which patients would achieve mucosal healing, clinical response, and clinical remission at weeks 6 and 30 of treatment. The gene expression signature identified patients who went on to achieve mucosal healing at treatment week 6 with an area under the receiver operating characteristic curve (AUCROC) of 0.688 (P = .002) and at week 30 with an AUCROC of 0.671 (P = .006). The signature identified patients with mucosal healing with 87% sensitivity, but only 34% specificity, limiting its clinical utility. The baseline gene expression signature did not identify patients who went on to achieve clinical remission or clinical response with statistical significance. Further studies are needed to identify biomarkers that can be used to predict which patients with UC will respond to treatment with anti-tumor necrosis factor agents. ClinicalTrials.gov no: NCT01988961.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Telesco SE, Brodmerkel C, Zhang H, et al. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology. 2018. PMID: 29981298. doi:10.1053/j.gastro.2018.06.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。